Observe Medical Asa (OBSRV) fair value: what the stock is really worth
We calculate from audited financials what Observe Medical Asa is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 18, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Observe Medical Asa for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Observe Medical ASA develops and commercialize medical technology products for patients, healthcare professionals, and hospitals in Europe, Asia, and the Americas.
Show more
Observe Medical ASA develops and commercialize medical technology products for patients, healthcare professionals, and hospitals in Europe, Asia, and the Americas. The company offers UnoMeter portfolio comprising Unometer, Safeti Plus, Unometer 500, and UnoMeter AbdoPressure products used for manual urine output measurement and for measuring intra-abdominal pressure. It also provides Sippi, a digital and automated urine measurement system for urine monitoring and biofilm control. Observe Medical ASA was founded in 2009 and is headquartered in Oslo, Norway.
Stock analysis
Observe Medical Asa (OBSRV) currently trades at kr 0.9300, while our model-based Fair Value estimate is kr 0.1275, implying the stock looks roughly 629.4% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.0935 (bear) to kr 0.1870 (bull), the price of kr 0.9300 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Observe Medical Asa reported revenue of 18.8M NOK in FY2025 versus 24.0M NOK in FY2021, a compound −5.9%/yr. Reported net income was −48.6M NOK in FY2025.
Key figures
Market cap 140M NOK (≈ $14.6M) · P/S ratio 7.42 · EPS (TTM) kr −0.7300 · Net margin −259% · Return on equity −190% · Return on assets (EBIT) −50.8% · Operating margin −319% · Revenue (TTM) 18.8M NOK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 68% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −86%, OBSRV screens richer than that median.
Fair Value models
Bear kr 0.0935Fair Value kr 0.1275Bull kr 0.1870
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.7%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.3%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−948.5% (2020) → −420.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−86% · Bottom 25%
Profitability
Return on assets−20% · Bottom 25%
Growth and dividend
Revenue growth43% · Top 25%
Balance sheet
Debt / equity0.67× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.49× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)0.78× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)100· sector 31
PAST (return on equity)0· sector 7
HEALTH (low debt)67· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Observe Medical Asa Fair Value". https://www.fairvalue-calculator.com/stock/OBSRV
Frequently asked questions
Is Observe Medical Asa (OBSRV) overvalued or undervalued?
As of Jul 18, 2026, our model estimates a fair value of kr 0.1275 versus a price of kr 0.9300, about −86% upside (overvalued).
What is the fair value of OBSRV?
Our model-based fair value for Observe Medical Asa is kr 0.1275 (as of Jul 18, 2026), built from audited fundamentals. The current price: kr 0.9300.
What is the quality score of OBSRV?
Observe Medical Asa has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Observe Medical Asa (OBSRV)?
Our model-based price target is the fair value of kr 0.1275 (as of Jul 18, 2026) from 1 valuation models. Cautious scenario kr 0.0935, optimistic scenario kr 0.1870. It is a calculation from audited fundamentals, not an analyst target.
What is the Observe Medical Asa stock forecast for 2026?
Our models put fair value at kr 0.1275, about −86% upside versus a price of kr 0.9300 (overvalued). Cautious scenario kr 0.0935, optimistic scenario kr 0.1870. The calculation is refreshed regularly with new filings.
What is the revenue of Observe Medical Asa (OBSRV)?
Observe Medical Asa reported trailing-twelve-month revenue of about 18.8M NOK (latest available figure, as of Jul 18, 2026).
What is the intrinsic value of Observe Medical Asa (OBSRV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Observe Medical Asa it is kr 0.1275 per share (as of Jul 18, 2026), against a price of kr 0.9300. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Observe Medical Asa stock overvalued or undervalued in 2026?
As of Jul 18, 2026, OBSRV trades above its calculated fair value: price kr 0.9300, fair value kr 0.1275, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OBSRV?
No. The price is what the market pays today (kr 0.9300); the fair value is what the company's own numbers justify (kr 0.1275). For Observe Medical Asa the two are kr 0.8025 per share apart. That gap is exactly why we show both numbers side by side.
How much is Observe Medical Asa worth?
The market values Observe Medical Asa at about 140M NOK (market capitalisation, as of Jul 18, 2026). Per share that is kr 0.9300; our models calculate a fair value of kr 0.1275 per share.
What do the bullish and bearish scenarios say about OBSRV?
Our models span a range for Observe Medical Asa: cautious scenario kr 0.0935, base kr 0.1275, optimistic kr 0.1870 per share (as of Jul 18, 2026, price kr 0.9300). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Observe Medical Asa (OBSRV)?
Balance-sheet figures for Observe Medical Asa (as of Jul 18, 2026): return on equity −190.4%, debt of 0.67 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is OBSRV from its 52-week high?
Observe Medical Asa trades at kr 0.9300, about 26% below its 52-week high of kr 1.25 and 68% above the low of kr 0.5550 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1275 is for.
Which stocks are comparable to Observe Medical Asa?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Observe Medical Asa stock attractive at the current price?
The data as of Jul 18, 2026: price kr 0.9300, calculated fair value kr 0.1275 (−86%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OBSRV calculated?
We run Observe Medical Asa through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.1275, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Observe Medical Asa itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Observe Medical Asa (OBSRV)?
The closing price on Sep 24, 2026 was kr 0.9300. Our model-based fair value is kr 0.1275, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Observe Medical Asa right now?
The price sits above even our optimistic bull case (kr 0.1870). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.0935 to kr 0.1870) leaves room in how you read the outcome.
Key figures of Observe Medical Asa
How large is the market capitalisation of Observe Medical Asa (OBSRV)?
The market capitalisation of Observe Medical Asa is 140M NOK (≈ $14.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Observe Medical Asa (OBSRV)?
The price-to-sales ratio of Observe Medical Asa is 7.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Observe Medical Asa (OBSRV)?
Earnings per share at Observe Medical Asa are kr −0.7300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Observe Medical Asa (OBSRV)?
The net margin of Observe Medical Asa is −259% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Observe Medical Asa (OBSRV)?
The return on equity (ROE) of Observe Medical Asa is −190% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Observe Medical Asa (OBSRV)?
On an EBIT basis the return on assets of Observe Medical Asa is −50.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Observe Medical Asa (OBSRV)?
The operating margin of Observe Medical Asa is −319% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Observe Medical Asa (OBSRV)?
Revenue at Observe Medical Asa is growing +42.6% versus a year earlier (3y avg −1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Observe Medical Asa (OBSRV) generate?
The free cash flow of Observe Medical Asa is −26.0M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Observe Medical Asa (OBSRV) carry?
The net debt of Observe Medical Asa is 19.2M NOK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Observe Medical Asa in the live analysis
One click puts Observe Medical Asa on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
